Drug intelligence / Profile preview

metyrosine

Development stage: Approved
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

Metyrosine is a tyrosine hydroxylase inhibitor used to treat excessive sympathetic stimulation in pheochromocytoma. It works by blocking the enzyme tyrosine hydroxylase, which is the rate-limiting step in catecholamine biosynthesis, thereby reducing the production of epinephrine and norepinephrine. This leads to decreased symptoms such as high blood pressure, headaches, sweating, and tachycardia associated with pheochromocytoma. Metyrosine is indicated for preoperative preparation for surgery in patients with pheochromocytoma, management when surgery is contraindicated, and chronic treatment of malignant pheochromocytoma[1][2][4].

Brand names: Demser
Other names: metyrosineDemser

Targets

TH (Tyrosine hydroxylase)

Beyond the preview

Go deeper on metyrosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metyrosine.

Explore the full profile